Reviews in Urology Volume 23, Issue 3 2024Leadership & Editorial Staff

LEADERSHIPEDITOR IN CHIEFNEAL D. SHORE, MDMedical Director
Carolina Urologic Research Center
Atlantic Urology Clinics

ASSOCIATE EDITORDAVID M. ALBALA, MDAssociated Medical Professionals
Chief of Urology, Crouse Hospital

HONORARY EDITOREVAN GOLDFISCHER, MD, MBAPresident of LUGPA
Director of Research, Urology Division
Premier Medical Group Clinical
Assistant Professor of Urology
New York Medical College
SECTION EDITORSPROSTATE CANCERASHLEY E. ROSS, MD, PHDAssociate Professor of Urology
Northwestern Feinberg School
of Medicine

BLADDER CANCERTOM JAYRAM, MDCo-Director, Advanced Therapeutics
Center at Urology Associates

KIDNEY CANCERSUMANTA K. PAL, MD, FASCOProfessor & Vice Chair of Academic Affairs
Department of Medical Oncology &Experimental Therapeutics
City of Hope Comprehensive Cancer Center

SECTION EDITORS
MEN’S HEALTHANDREW Y. SUN, MDDirector, Center for Men’s Health
Urology Partners of North Texas

WOMEN’S HEALTHKARI H. BAILEY, MDUrologist
Anne Arundel Urology

BUSINESS OF UROLOGYKIRSTEN ANDERSON, MHA, CMPE, CPC, CASCChief Executive Officer
Oregon Urology Institute
Oregon SurgiCenter

HEALTH POLICYMARA R. HOLTON, MDChief Executive Officer
Anne Arundel Urology

PATIENT NAVIGATIONMARCO CARLOS, MA, OPN-CGAssistant VP, Clinical Development
Urology Austin

TECHNOLOGY/ARTIFICIAL INTELLIGENCEJULIAN HONG, MD, MSAssistant Professor
Department of Radiation Oncology
University of California San Francisco

SECTION EDITORSADVANCED PRACTICE CLINICIANSKENNETH A. MITCHELL, MPAS, PA-CErlanger Urology
Male Reproductive & Sexual Medicine Clinic
GUYnecology Men’s Health Founder & CEO

CODING & REIMBURSEMENTJONATHAN N. RUBENSTEIN, MDChief Compliance Officer
United Urology Group

MANAGING EDITORJEFFREY ARNOLDOpt-in Communications, LLC
CONTRIBUTING EDITORSStephen Freedland, MDCeleste Kirshner, CAE, MHSADaniel George, MDBryan Mehlhaff, MDHiten D. Patel, MD, MPHJeffrey J. Tosoian, MD, MPHNathan Diller, FACHE, CMPEMark PainterRonney Abaza, MD, FACSVahan Kassabian, MD
Specialty Networks, LLC
600 Superior Avenue, Suite 1500
Cleveland, OH 44114STATEMENT OF EDITORIAL PURPOSEReviews in Urology is designed to review the latest advances in the diagnosis and treatment of a wide range of urologic conditions to help the busy, practicing urologist keep up-to-date with the rapidly evolving field of urology.
REVIEWS IN UROLOGY (ISSN 1523-6161 [print]; ISSN 2153-8182 [online]) is published 4 times a year by Specialty Networks, LLC, 600 Superior Avenue, Suite 1500, Cleveland, Ohio 44114. Copyright© 2024 by Specialty Networks, LLC. Reproduction by magnetic, electronic, or other means is strictly prohibited by law. Violation of copyright will result in legal action. Fees may be subject to change. Reviews in Urology is an independent publication under the editorial control of Specialty Networks, LLC and its editorial board. Scientific rigor is enforced through a process of review that evaluates information presented for fair balance, objectivity, independence, and relevance to educational need. All articles are reviewed by at least two experts in the field. The opinions expressed in this publication are those of the contributors and are not attributable to the publisher, editor, editorial board, or advertisers of Reviews in Urology. The authors, editors, publisher, their servants, assigns, or agents, shall not be in any way liable for the currency of information or for any errors, omissions, or inaccuracies in the publication. Clinical judgment must guide each physician in weighing the benefits of treatment against the risk of toxicity. Information in this publication should not be relied upon in the care of patients. The publisher cannot be held responsible for any injury or damage to persons or property from any use of methods, products, instructions, or ideas contained in this publication. Although articles in this issue of the journal may contain discussion of investigational uses of agents that are not approved by the FDA, these are the views of the author(s) and do not necessarily represent those of Specialty Networks, LLC. Please refer to the official prescribing information for each product for indications, contraindications, and warnings. Specialty Networks, LLC does not recommend the use of any agent outside of the labeled indications. Every effort has been made by the authors and contributors to contact holders of copyright to obtain permission to reproduce copyrighted material. However, if any have been inadvertently overlooked, the publication will be pleased to make the necessary arrangements at the first opportunity. The appearance of advertising has no influence on editorial content or presentation and does not imply endorsement of products by the publication or its editors.Reprint Requests: Please contact the journal directly at RIU@specialtynetworks.comThis paper meets the requirements of ANSI/NISO Z39.48-1992 (R2009) [Permanence of Paper] effective with Volume 23, Issue 1, Spring 2024.
CoverKEYTRUDAKEYTRUDA 2KEYTRUDA 3KEYTRUDA 4KEYTRUDA 5KEYTRUDA 6KEYTRUDA 7LUGPAJELMYTOJELMYTO 2Pfizer OncologyPfizer Oncology 2Leadership & Editorial StaffContentsLUGPA 2025Letter From the President of LUGPAPARP Resource GuideLUGPA NewsCorrectionIsoPSAAdvances in Radical Prostatectomy: A Narrative ReviewDarolutamide for the Management of Metastatic Hormone- Sensitive Prostate Cancer: A Urologist-Oncologist PerspectiveRecent Advances in Managing Pediatric Neurogenic Bladder due to Spina BifidaIncorporation of IsoPSA Into Clinical Practice in the Management of Elevated Prostate- Specific Antigen Based on Current GuidelinesResponse to Targeted Therapy and Checkpoint Inhibition in a Patient With Mucinous Tubular and Spindle Cell Carcinoma: A Case Report and Literature ReviewCiplaImmune Checkpoint Inhibitors for the Treatment of Non–Muscle-Invasive Bladder Cancer: An Overview of Ongoing Clinical TrialsThe Business of Independent Urologic Medicine: Caring for Patients While Operating a Business in a Post–COVID-19 Era of Private PracticeThe Specialty Networks Localized to High- Risk Biochemically Recurrent Prostate Cancer Patient PlaybookLocalized to High-Risk/Biochemically Recurrent Prostate CancerMeet the Expert: Shelby Moneer, MS, CHES, from ZERO Prostate CancerPPS AnalyticsWELIREGWELIREG 2WELIREG 3WELIREG 4WELIREG 5WELIREG 6Pfizer Urology Oncology